Food and Drug Administration, US Departement of Health and Human Services. Clinical trial endpoints for the approval of Non -Small Cell Lung Cancer Drugs and Biologics – Guidance OSE2101 Protocol OSE2101C301 Confidential Version n°6.0 Page 82 of 101 02 February 2022 for industry April 2015. [Accessed 19 July 2015].